Stock Ratings / Health Care / PAHC / earnings

GPCR (42) OCUL (37) INVA (75) ETON (62) ⌘ Pro Terminal →

Phibro Animal Health Corporation (Class A) (PAHC) Next Earnings Date & Expected ±7.6% Move

$38.86 +2.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Phibro Animal Health Corporation (Class A) (PAHC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $1.58B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PAHC)Realized 20D OHLCV Swing Band: ±7.6%

NEXT EST. WINDOW: Dec 28, 2026 (~56 DAYS)

Historical OHLCV Volatility ±7.6% Swing Band

±$2.95 Expected Swing

MODEL EARNINGS SETUP GAUGE

PAHC Quantitative Pre-Earnings Setup: 68/100

Trailing EPS: $1.19 • YoY Revenue Growth: 27.4%

Model Bullish Setup (68/100)Model Risk Weight (32/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-06-30	$1.30B	$48.3M	$80.1M	30.9%
FY 2024	2024-06-30	$1.02B	$2.4M	$87.6M	30.8%
FY 2023	2023-06-30	$977.9M	$32.6M	$13.3M	30.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating PAHC & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on PAHC
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PAHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.93%⚡ TESTING RESISTANCE

2026-10-30O $39.38H $39.95L $38.49C $38.86VOL 182.8K

RES: $40.91SUP: $34.09SMA50: $36.99SMA200: $41.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PAHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PAHC Butterfly Map → + Track PAHC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PAHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PAHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PAHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAHC)

Health Care Rank #108 of 1016 ⚔️ GPCR vs PAHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PAHC vs. GPCR, OCUL, INVA, ETON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Phibro Animal Health Corporation (Class A) (PAHC) ranks #108 by composite RQD confidence (68/100, grade C+) and #300 by equity capitalization ($1.58B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PAHC at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PAHC ACTIVE Phibro Animal Health Corporation (Class A)	C+	68/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	Benchmark Subject
GPCR Structure Therapeutics Inc.	D-	42/100	—	—	-19.5%	+2.14%	$1.56B	/gpcr-vs-pahc →
OCUL Ocular Therapeutix Inc.	D-	37/100	—	87.3%	-35.0%	+0.27%	$1.61B	/ocul-vs-pahc →
INVA Innoviva Inc.	B	75/100	—	74.8%	14.7%	+0.90%	$1.54B	/inva-vs-pahc →
ETON Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	/eton-vs-pahc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001069899

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Phibro Animal Health Corporation (Class A) (PAHC) reported GAAP revenue of $1.30B (+27.4% vs. FY2024 revenue of $1.02B , and +32.6% cumulative change since FY2023) , GAAP net income of $48.3M, operating cash flow of $80.1M, and free cash flow of $80.1M (-8.5% YoY). On the balance sheet, PAHC closed FY2025 with $1.41B in total assets against $603.6M in total debt (Altman Z-Score: 2.87, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$1.30B	$48.3M	$80.1M	$80.1M	$1.41B	$603.6M
FY2024 (FY)	2024-06-30	$1.02B	$2.4M	$87.6M	$87.6M	$1.29B	$622.9M
FY2023 (FY)	2023-06-30	$977.9M	$32.6M	$13.3M	$13.3M	—	—

3. PAHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Phibro Animal Health Corporation (Class A) (NASDAQ: PAHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $38.86 (+2.59% 1D, market cap $1.58B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, PAHC ranks #108 in composite RQD confidence.

How does PAHC compare to GPCR and OCUL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PAHC carries a Roarable C+ (68/100 RQD), trailing P/E of 32.7x, gross margin of 30.9%, and ROIC of 9.9%. By comparison, GPCR (Structure Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B) and OCUL (Ocular Therapeutix Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PAHC?

Per PAHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001069899), Phibro Animal Health Corporation (Class A) generated $1.30B in revenue (+27.4% YoY), $48.3M in net income, and $80.1M in free cash flow against $1.41B in total assets and $603.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PAHC trading relative to its 50-day, 200-day, and 52-week technical levels?

PAHC last traded at $38.86 (+2.59% on volume of 100,844 shares), positioning the stock +5.06% above its 50-day simple moving average ($36.99) and -5.82% below its 200-day simple moving average ($41.26). Across its 52-week range of $28.25 to $60.08, PAHC sits at the 33.3% percentile with a 14-day RSI of 56.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.6% ($35.91 to $41.81).

PAHC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is PAHC's next earnings date?

Based on SEC filing cadence, Phibro Animal Health Corporation (Class A) (PAHC)'s next quarterly reporting window is estimated around Dec 28, 2026.

How much is PAHC stock expected to move on earnings?

Volatility modeling currently projects a ±7.6% event move for PAHC, spanning a range between $35.91 and $41.81.

Direct Sub-Reports: PAHC RQD Cockpit PAHC 12M Forecast PAHC Earnings & Move PAHC Dividends & DRIP PAHC Insiders & 13F PAHC Whale Options PAHC Profit Sankey PAHC News & Why